E. Cramer

Troponin I release at rest and after exercise in patients with hypertrophic cardiomyopathy and the effect of betablockade.

J. Timmermans, F. Verheugt, H. Bos, 2006, Archivos de cardiologia de Mexico.

Acute rule-out of non–ST-segment elevation acute coronary syndrome in the (pre)hospital setting by HEART score assessment and a single point-of-care troponin: rationale and design of the ARTICA randomised trial

P. Damman, E. Adang, R. V. van Geuns, 2020, BMJ Open.

Cohort profile of BIOMArCS: the BIOMarker study to identify the Acute risk of a Coronary Syndrome—a prospective multicentre biomarker study conducted in the Netherlands

R. D. de Winter, R. J. Winter, P. Harst, 2016, BMJ Open.

Temporal Evolution of Serum Concentrations of High‐Sensitivity Cardiac Troponin During 1 Year After Acute Coronary Syndrome Admission

R. D. de Winter, M. Simoons, P. van der Harst, 2020, Journal of the American Heart Association.

Temporal Pattern of Growth Differentiation Factor-15 Protein After Acute Coronary Syndrome (From the BIOMArCS Study).

P. van der Harst, E. Boersma, R. Oemrawsingh, 2019, The American journal of cardiology.

High-Frequency Biomarker Measurements of Troponin, NT-proBNP, and C-Reactive Protein for Prediction of New Coronary Events After Acute Coronary Syndrome.

R. D. de Winter, M. Simoons, P. van der Harst, 2019, Circulation.

Elevated high-sensitivity cardiac troponin is associated with hypertrophy and fibrosis assessed with CMR in patients with hypertrophic cardiomyopathy

J. Bakker, F. Verheugt, M. Brouwer, 2013, Journal of Cardiovascular Magnetic Resonance.